BillionToOne
QCT-based molecular diagnostics for prenatal, oncology
Product Management Intern - Software Engineering
About the job
- Currently pursuing a Master’s degree, ideally in business administration, biological sciences, engineering, or other related field
- Experience in biotechnology or healthcare industry preferred
- Command of product principles, techniques, and best practices
- Solid analytical skills to interpret internal data and leverage external data sources
- Comfortable working with highly technical teams, including software engineers, bioinformaticians, and data scientists
- Excellent communication (verbal and written) and interpersonal skills, with the ability to collaborate effectively across teams and communicate complex concepts to stakeholders
- Ability to adapt to an ambiguous and evolving internal and external environment
- Product strategy and planning: Collaborate cross-functionally to develop product strategy, define success criteria, and create roadmaps.
- Data analysis: Conduct data analysis to inform a product roadmap and provide strategic recommendations.
- Project management and execution: Deliver quality products through scope definition, agile project management, and effective stakeholder communication.
- Communication and documentation: Create detailed specifications for the project team and develop clear business and technical documentation to support project efforts. Foster relationships across multiple teams, manage expectations, and communicate upwards.
- Collaboration with internal stakeholders: Closely collaborate with internal teams (including Client Services, Sales, Genetic Counseling, Software Engineering, and Lab personnel) to understand user requirements and facilitate project communication.
About the company
BillionToOne provides molecular diagnostic testing for prenatal screening and cancer monitoring. Its QCT technology detects and measures DNA variations at a single base-pair level, enabling precise analysis across the three billion DNA letters. The main products, Northstar Select and Northstar Response, are tests that help doctors choose the best first-line therapy and track how well treatment is working, respectively. The company markets these services to healthcare providers who perform the tests and use the results to guide patient care. Unlike some rivals, BillionToOne emphasizes high-resolution DNA assessment and scalable diagnostic services through provider partnerships, aiming to improve accuracy, speed, and access. Its mission is to make molecular testing more accurate, efficient, and accessible to all, driven by growth, equality, and teamwork.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Menlo Park, California
Founded
2016
Get referred to BillionToOne
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue rose 64% to $109.4 million; guidance stayed $450–$465 million.
- Oncology revenue jumped 176% in Q2 2026 after Northstar expansion and Origin launch.
- Anthem in-network access and Epic integration broaden distribution across roughly 300 million lives.
What critics are saying
- Illumina sued BillionToOne in Delaware on May 7, 2026 for patent infringement.
- CEO Oguzhan Atay sold his direct stake in September 2026 while shares neared $116.
- FDA enforcement threatens LDT-based Northstar and UNITY products if regulators tighten oversight.
What makes BillionToOne unique
- BillionToOne’s single-molecule counting platform powers UNITY Complete, Northstar Select, and Northstar Response.
- September 1, 2026 Northstar Origin predicts tissue-of-origin from one blood draw.
- Epic integration embeds ordering and results across prenatal and oncology workflows.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Competitive pay
Retirement savings package
Parental leave
Free snacks & lunches
Medical, dental, & vision premiums
On campus perks
Free-on-site EV charging
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%BillionToOne's stock jumped 12% to $116 on 22 September without any company announcement, extending a rally from $100 on 14 September. The prenatal and cancer diagnostic testing company last reported results in early August, showing second-quarter revenue up 64% year-on-year to $109.4 million with gross margin at 70%. The company's CEO and general counsel sold approximately 60,000 shares for roughly $6.5 million in mid-September at prices between $98 and $110. The stock now trades just 3% below the Street's $120 mean target, down from 68% upside at the end of 2025. BillionToOne maintained its 2026 revenue guidance of $450 million to $465 million. The oncology division grew 176% to $13.7 million, whilst the prenatal business increased 55% to $94.2 million.
John Roderick Ten Bosch, SVP of Laboratory Operations at BillionToOne, sold 1,416 shares of Class A Common Stock on 9 September 2026 at a weighted average price of $97.54, according to an SEC filing. The transaction was conducted under a Rule 10b5-1 plan adopted in June 2026. Following the sale, Ten Bosch retains 25,051 shares valued at $2.4 million. The sale represents a single-digit percentage of his total holdings. BillionToOne, a Menlo Park-based diagnostics company, has a $4.6 billion market capitalisation. The company reported revenue of $397 million and net income of $32 million. Revenue surged 64% year over year in the second quarter, with analysts expecting approximately 37% annualised growth over the next two years.
BillionToOne CEO Oguzhan Atay sold 30,331 Class A shares on 14 September 2026 for approximately $3 million, liquidating his entire directly held stake in the company. The sale was executed under a pre-established Rule 10b5-1 trading plan adopted in June 2026. The transaction primarily involved a cashless exercise of 24,999 options at $2.80 per share, with immediate sale of resulting shares. Atay's spouse sold an additional 5,332 shares. The weighted average sale price was $99.91. Despite disposing of directly held shares, Atay retains about 500,000 fully vested stock options and holds approximately 157,000 shares indirectly through his spouse. The Menlo Park-based molecular diagnostics company reported $109.4 million revenue in Q2 2026, representing 64% year-over-year growth, with full-year revenue forecast between $450 million and $465 million.
BillionToOne has launched Northstar Origin, a liquid biopsy add-on test that predicts tissue of origin from circulating cell-free DNA for patients with cancer of unknown primary or uncertain cancer diagnosis. The test requires no additional tissue or separate blood draws beyond what's already collected for therapy selection. In a validation study of 1,578 patients, Northstar Origin identified the correct tissue of origin as its top prediction in 87% of cases and within its top three predictions in 91% of cases. The classifier was developed using 6,025 blood samples from advanced cancer patients. The company also expanded its Northstar Select panel from 84 to 102 genes, adding 18 new genes including MTAP deletion. The test is designed to help community oncologists make diagnostic decisions, as roughly 3-5% of new cancer diagnoses present as cancer of unknown primary.
David Tsao, co-founder and chief technology officer of BillionToOne, sold 10,000 shares of Class A Common Stock for $1 million on 25 August 2026. The transaction involved a cashless exercise of fully vested stock options at $2.80 per share, with the resulting shares sold at a weighted average price of $100. The sale was executed under a Rule 10b5-1 trading plan adopted in March 2026, indicating it was pre-scheduled rather than discretionary. Tsao retains 1,000 direct shares and 580,000 stock options. BillionToOne, a Menlo Park-based molecular diagnostics company, reported second-quarter revenue of $109.4 million, representing 64% year-over-year growth. The company has a market capitalisation of $4.4 billion and generated $397.4 million in trailing 12-month revenue with $33.5 million in net income.